Zydus Lifesciences (BOM:532321) Interest Expense : ₹-812 Mil (TTM As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Zydus Lifesciences's interest expense for the three months ended in Mar. 2024 was ₹ -346 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ₹-812 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Zydus Lifesciences's Operating Income for the three months ended in Mar. 2024 was ₹ 14,199 Mil. Zydus Lifesciences's Interest Expense for the three months ended in Mar. 2024 was ₹ -346 Mil. Zydus Lifesciences's Interest Coverage for the quarter that ended in Mar. 2024 was 41.04. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zydus Lifesciences Interest Expense Historical Data

The historical data trend for Zydus Lifesciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Interest Expense Chart

Zydus Lifesciences Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Interest Expense

Get a 7-Day Free Trial

-3,236.00

-1,559.00

-1,144.00

-1,299.00

-812.00

Zydus Lifesciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-277.00	-181.00	-87.00	-198.00	-346.00

Zydus Lifesciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-812 Mil.

Zydus Lifesciences (BOM:532321) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zydus Lifesciences's Interest Expense for the three months ended in Mar. 2024 was ₹-346 Mil. Its Operating Income for the three months ended in Mar. 2024 was ₹14,199 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ₹251 Mil.

Zydus Lifesciences's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	14199	/	-346
	=	41.04

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Zydus Lifesciences Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Zydus Lifesciences (BOM:532321) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Interest Expense

Traded in Other Exchanges

ZYDUSLIFE:India

Address

Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481

Website

https://www.zyduslife.com

Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines